Alx Oncology Holdings Inc financial data

Symbol
ALXO on Nasdaq
Industry
Pharmaceutical Preparations
Location
323 Allerton Avenue, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 516 % -32.1%
Debt-to-equity 32.6 % +50.8%
Return On Equity -94 % -18.6%
Return On Assets -70.9 % -8.78%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.4M shares +6.45%
Common Stock, Shares, Outstanding 53.1M shares +6.21%
Entity Public Float 251M USD +55.6%
Common Stock, Value, Issued 53K USD +6%
Weighted Average Number of Shares Outstanding, Basic 52.2M shares +21.4%
Weighted Average Number of Shares Outstanding, Diluted 52.2M shares +21.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 116M USD -17.9%
General and Administrative Expense 26.1M USD -8.39%
Operating Income (Loss) -142M USD +16.3%
Net Income (Loss) Attributable to Parent -135M USD +16.1%
Earnings Per Share, Basic -2.58 USD/shares +31%
Earnings Per Share, Diluted -2.58 USD/shares +31%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.6M USD -21.6%
Other Assets, Current 27K USD -93.9%
Assets, Current 134M USD -28.8%
Property, Plant and Equipment, Net 2.91M USD -19.1%
Operating Lease, Right-of-Use Asset 4.02M USD -17%
Other Assets, Noncurrent 6.99M USD -53%
Assets 148M USD -39.1%
Accounts Payable, Current 4.5M USD -47.7%
Employee-related Liabilities, Current 5.31M USD -12.5%
Liabilities, Current 18.5M USD -48.6%
Operating Lease, Liability, Noncurrent 3.46M USD -21.5%
Other Liabilities, Noncurrent 6.19M USD -14.1%
Liabilities 34.2M USD -35.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 275K USD +7.42%
Retained Earnings (Accumulated Deficit) -621M USD -27.7%
Stockholders' Equity Attributable to Parent 114M USD -40.1%
Liabilities and Equity 148M USD -39.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.9M USD -36.3%
Net Cash Provided by (Used in) Financing Activities 3.09M USD
Net Cash Provided by (Used in) Investing Activities 26.5M USD -37.4%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 53.1M shares +6.21%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.6M USD -21.5%
Deferred Tax Assets, Valuation Allowance 129M USD +34.4%
Operating Lease, Liability 4.41M USD -16.1%
Payments to Acquire Property, Plant, and Equipment 148K USD -78.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -135M USD +15.6%
Lessee, Operating Lease, Liability, to be Paid 5.47M USD -18.8%
Property, Plant and Equipment, Gross 4.98M USD +3.23%
Operating Lease, Liability, Current 949K USD +12%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.06M USD -28.3%
Deferred Tax Assets, Operating Loss Carryforwards 41.1M USD +55%
Unrecognized Tax Benefits 4.11M USD +31.7%
Operating Lease, Payments 313K USD +0.97%
Depreciation, Depletion and Amortization 214K USD +0.47%
Deferred Tax Assets, Net of Valuation Allowance 131M USD +33.6%
Share-based Payment Arrangement, Expense 27.1M USD +3.12%
Interest Expense 1.73M USD +10.5%